Antimuscarinics for treatment of storage lower urinary tract symptoms in men: A systematic review

International Journal of Clinical Practice

Volumn 65, Issue 4, 2011, Pages 487-507

  Kaplan, Steven A ^a   Roehrborn, C G ^b   Abrams, P ^c   Chapple, C R ^d   Bavendam, T ^e   Guan, Z ^e  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c SOUTHMEAD HOSPITAL   (United Kingdom)

^d ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^e PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; DUTASTERIDE; FESOTERODINE; MUSCARINIC RECEPTOR BLOCKING AGENT; NAFTOPIDIL; OXYBUTYNIN; PLACEBO; PROPIVERINE; PROSTATE SPECIFIC ANTIGEN; SOLIFENACIN; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN; TOLTERODINE;

COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; LOWER URINARY TRACT SYMPTOM; MONOTHERAPY; OVERACTIVE BLADDER; POST HOC ANALYSIS; POSTVOID RESIDUAL URINE VOLUME; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REVIEW; SYSTEMATIC REVIEW; URINE FLOW RATE; URINE RETENTION;

ADRENERGIC ALPHA-AGONISTS; DRUG THERAPY, COMBINATION; HUMANS; LOWER URINARY TRACT SYMPTOMS; MALE; MUSCARINIC ANTAGONISTS; PROSTATIC HYPERPLASIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TREATMENT OUTCOME;

EID: 79952765099     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2010.02611.x     Document Type: Review

References (54)

1. McVary KT. BPH: epidemiology and comorbidities. Am J Manag Care 2006; 12: S122-8.
2. Parsons JK, Bergstrom J, Silberstein J, Barrett-Connor E. Prevalence and characteristics of lower urinary tract symptoms in men aged > or = 80 years. Urology 2008; 72: 318-21.
3. Abdel-Aziz KF, Lemack GE. Overactive bladder in the male patient: bladder, outlet, or both? Curr Urol Rep 2002; 3: 445-51.
4. Athanasopoulos A, Mitropoulos D, Giannitsas K, Perimenis P. Safety of anticholinergics in patients with benign prostatic hyperplasia. Expert Opin Drug Saf 2008; 7: 473-9.
5. Abrams P, Cardozo L, Fall M et al. The standardisation of terminology in lower urinary tract function: report from the standardisation subcommittee of the International Continence Society. Urology 2003; 61: 37-49. (Pubitemid 36151708)
6. Abrams P, Artibani W, Cardozo L et al. Reviewing the ICS 2002 Terminology Report: the ongoing debate. Neurourol Urodyn 2006; 25: 293.
7. Rosier PF, de la Rosette JJ, Koldewijn EL et al. Variability of pressure-flow analysis parameters in repeated cystometry in patients with benign prostatic hyperplasia. J Urol 1995; 153: 1520-5.
8. Hyman MJ, Groutz A, Blaivas JG. Detrusor instability in men: correlation of lower urinary tract symptoms with urodynamic findings. J Urol 2001; 166: 550-2.
9. Oelke M, Baard J, Wijkstra H et al. Age and bladder outlet obstruction are independently associated with detrusor overactivity in patients with benign prostatic hyperplasia. Eur Urol 2008; 54: 419-26.
10. Milsom I, Abrams P, Cardozo L et al. How wide-spread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001; 87: 760-6.
11. Stewart WF, Van Rooyen JB, Cundiff GW et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003; 20: 327-36. (Pubitemid 44175300)
12. Irwin DE, Milsom I, Hunskaar S et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006; 50: 1306-15.
13. Elinoff V, Bavendam T, Glasser DB et al. Symptom-specific efficacy of tolterodine extended release in patients with overactive bladder: the IMPACT trial. Int J Clin Pract 2006; 60: 745-51. (Pubitemid 43811659)
14. Chapple CR, Roehrborn CG. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol 2006; 49: 651-9.
15. Armitage J, Emberton M. The role of anticholinergic drugs in men with lower urinary tract symptoms. Curr Opin Urol 2008; 18: 11-5. (Pubitemid 350307524)
16. Rosenberg MT, Staskin DR, Kaplan SA et al. A practical guide to the evaluation and treatment of male lower urinary tract symptoms in the primary care setting. Int J Clin Pract 2007; 61: 1535-46. (Pubitemid 47228616)
17. Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU Int 2007; 100: 987-1006. (Pubitemid 47537675)
18. Liberati A, Altman DG, Tetzlaff J et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009; 151: W65-94.
19. Kaplan SA, Roehrborn CG, Rovner ES et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 2006; 296: 2319-28. (Pubitemid 44749359)
20. Rovner ES, Kreder K, Sussman DO et al. Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms. J Urol 2008; 180: 1034-41.
21. Kaplan SA, Roehrborn CG, Chancellor M et al. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score. BJU Int 2008; 102: 1133-9.
22. Roehrborn CG, Kaplan SA, Jones JS et al. Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size. Eur Urol 2009; 55: 472-81.
23. Roehrborn CG, Kaplan SA, Kraus SR et al. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB. Urology 2008; 72: 1061-7, discussion 7.
24. Chapple C, Herschorn S, Abrams P et al. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with a-blockers. Eur Urol 2009; 56: 534-43.
25. Chapple CR, Herschorn S, Abrams P et al. Efficacy and safety of tolterodine extended-release in men with overactive bladder symptoms treated with an alpha-blocker: effect of baseline prostate-specific antigen concentration. BJU Int 2010; 106: 1332-8.
26. Athanasopoulos A, Gyftopoulos K, Giannitsas K et al. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol 2003; 169: 2253-6. (Pubitemid 36576764)
27. Lee JY, Kim HW, Lee SJ et al. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int 2004; 94: 817-20. (Pubitemid 39472476)
28. Yang Y, Zhao XF, Li HZ et al. Efficacy and safety of combined therapy with terazosin and tolterodine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study. Chin Med J (Engl) 2007; 120: 370-4. (Pubitemid 46488346)
29. Chung DE, Te AE, Staskin DR, Kaplan SA. Efficacy and safety of tolterodine extended release and dutasteride in male overactive bladder patients with prostates >30 grams. Urology 2010; 75: 1144-8.
30. Hofner K, Burkart M, Jacob G, Jonas U. Safety and efficacy of tolterodine extended release in men with overactive bladder symptoms and presumed nonobstructive benign prostatic hyperplasia. World J Urol 2007; 25: 627-33.
31. Hofner K, Burkart M, Jacob G, Jonas U. Symptomatic and quality of life response to tolterodine in subgroups of men with overactive bladder symptoms and presumed non-obstructive benign prostatic hyperplasia. World J Urol 2010; 28: 353-7.
32. Abrams P, Kaplan SA, De Koning Gans HJ, Millard R. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 2006; 175: 999-1004.
33. Kaplan SA, Walmsley K, Te AE. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 2005; 174: 2273-6.
34. Kaplan SA, Roehrborn CG, Dmochowski R et al. Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia. Urology 2006; 68: 328-32. (Pubitemid 44175507)
35. Roehrborn CG, Abrams P, Rovner ES et al. Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence. BJU Int 2006; 97: 1003-6.
36. Michel MC, Schneider T, Krege S, Goepel M. Does gender or age affect the efficacy and safety of tolterodine? J Urol 2002; 168: 1027-31.
37. MacDiarmid SA, Peters KM, Chen A et al. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. Mayo Clin Proc 2008; 83: 1002-10.
38. Staskin DR, Rosenberg MT, Dahl NV et al. Effects of oxybutynin transdermal system on health-related quality of life and safety in men with overactive bladder and prostate conditions. Int J Clin Pract 2008; 62: 27-38. (Pubitemid 350294017)
39. Yokoyama T, Uematsu K, Watanabe T et al. Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study. Scand J Urol Nephrol 2009; 43: 307-14.
40. Lee KS, Choo MS, Kim DY et al. Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. J Urol 2005; 174: 1334-8.
41. Ronchi P, Gravina GL, Galatioto GP et al. Urodynamic parameters after solifenacin treatment in men with overactive bladder symptoms and detrusor underactivity. Neurourol Urodyn 2009; 28: 52-7.
42. Kaplan SA, McCammon K, Fincher R et al. Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. J Urol 2009; 182: 2825-30.
43. Kaplan SA, Goldfischer ER, Steers WD et al. Solifenacin treatment in men with overactive bladder: effects on symptoms and patient-reported outcomes. Aging Male 2010; 13: 100-7.
44. Herschorn S, Jones JS, Oelke M et al. Efficacy and tolerability of fesoterodine in men with overactive bladder: a pooled analysis of 2 phase III studies. Urology 2010; 75: 1149-55.
45. Malhotra BK, Wood N, Sachse R. Influence of age, gender, and race on pharmacokinetics, pharmacodynamics, and safety of fesoterodine. Int J Clin Pharmacol Ther 2009; 47: 570-8.
46. Roehrborn CG. Definition of at-risk patients: baseline variables. BJU Int 2006; 97(Suppl. 2): 7-11, discussion 21-2.
47. Martín-Merino E, García-Rodríguez LA, Masso-Gonzalez EJ, Roehrborn CG. Do oral antimuscarinic drugs carry an increased risk of acute urinary retention? J Urol 2009; 182: 1442-8.
48. Irwin DE, Milsom I, Kopp Z et al. Prevalence, severity, and symptom bother of lower urinary tract symptoms among men in the EPIC study: impact of overactive bladder. Euro Urol 2009; 56: 14-20.
49. Laniado ME, Ockrim JL, Marronaro A et al. Serum prostate-specific antigen to predict the presence of bladder outlet obstruction in men with urinary symptoms. BJU Int 2004; 94: 1283-6. (Pubitemid 40052094)
50. Machino R, Kakizaki H, Ameda K et al. Detrusor instability with equivocal obstruction: a predictor of unfavorable symptomatic outcomes after transurethral prostatectomy. Neurourol Urodyn 2002; 21: 444-9.
51. Blake-James BT, Rashidian A, Ikeda Y, Emberton M. The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and metaanalysis. BJU Int 2007; 99: 85-96. (Pubitemid 44915626)
52. Irwin DE, Milsom I, Kopp Z et al. Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries. BJU Int 2006; 97: 96-100.
53. Peters TJ, Donovan JL, Kay HE et al. The International Continence Society 'Benign Prostatic Hyperplasia' Study: the bothersomeness of urinary symptoms. J Urol 1997; 157: 885-9.
54. McConnell JD, Roehrborn CG, Bautista OM et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 2387-98. (Pubitemid 37542987)